Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SparX’s Lead Claudin 18.2 mAb Candidate Included in CAR-iNKT Cell Therapy

publication date: Oct 16, 2023

SparX Group, a Chicago company with China subsidiaries, announced that SPX-101, a Claudin 18.2 mAb, will be part of an off-the-shelf CAR-iNKT cell therapy developed by Arovella Therapeutics of South Africa. Invariant Natural Killer T (iNKT) cells are a specialized T cell subset known for recognizing lipid antigens via the CD1d molecule. Headquartered in Chicago, SparX has four major operating entities: a Delaware R&D operation, a Hong Kong business development company, a major process development and commercial production facility in Yangzhou, and a Shanghai drug registration and marketing subsidiary. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital